H-D-Arg-OH是一种D-构型的非天然氨基酸,在药物开发和蛋白质工程中具有重要应用。
Cas No.:157-06-2
Sample solution is provided at 25 µL, 10mM.
H-D-Arg-OH is a D-configuration non-natural amino acid with important applications in drug development and protein engineering[1-2]. H-D-Arg-OH is commonly used in studies related to the L-arginine/nitric oxide pathway and has shown potential in inhibiting the proliferation of certain cancer cells[3-4].
In vitro, pretreatment of pituitary GH3 cells with H-D-Arg-OH (10mM) for 15–240 minutes, followed by incubation in normal Krebs solution, significantly increased intracellular D-arginine concentration and nitric oxide (NO) production, while also elevating extracellular nitrite levels[5]. Combined pretreatment of Actinomyces viscosus biofilms with 8mM H-D-Arg-OH and 0.01% α-amylase (Amy) for 30 minutes significantly enhanced the dissociation effect of α-amylase on the biofilm, completely hydrolyzing extracellular polysaccharides while maintaining safety toward MC3T3-E1 pre-osteoblasts[6].
In vivo, oral administration of H-D-Arg-OH (1000mg/kg/day) via drinking water to 9-week-old male Sprague-Dawley rats for 16 weeks significantly increased endothelial nitric oxide synthase (eNOS) protein expression in the kidneys and aorta, while also raising urea levels in skeletal muscle[7]. After oral administration of H-D-Arg-OH (6mmol/10mL DW/kg) to ICR mice for 30, 60, and 90 minutes, a significant increase in H-D-Arg-OH levels was observed in both plasma and brain tissues[8].
References:
[1] Navarro E, Alonso SJ, Martín FA, et al. Toxicological and pharmacological effects of D-arginine. Basic Clin Pharmacol Toxicol. 2005 Sep;97(3):149-54.
[2] Kawabata A, Nishimura Y, Takagi H. L-leucyl-L-arginine, naltrindole and D-arginine block antinociception elicited by L-arginine in mice with carrageenin-induced hyperalgesia. Br J Pharmacol. 1992 Dec;107(4):1096-101.
[3] Hu B, Feng X, Wang L, et al. 5-BDBD ameliorates an OVA-induced allergic asthma by the reduction of Th2 cytokines production. Iran J Basic Med Sci. 2018 Apr;21(4):364-369.
[4] Wang L, Wu J, Wang B, et al. d-arginine-functionalized carbon dots with enhanced near-infrared emission and prolonged metabolism time for tumor fluorescent-guided photothermal therapy. J Colloid Interface Sci. 2025 Jan 15;678(Pt C):575-582.
[5] Melisi D, Secondo A, Montoro P, et al. Galactosyl derivatives of L-arginine and D-arginine: synthesis, stability, cell permeation, and nitric oxide production in pituitary GH3 cells. J Med Chem. 2006 Aug 10;49(16):4826-33.
[6] Li B, Cai Q, Wang Z, et al. D-arginine Enhances the Effect of Alpha-Amylase on Disassembling Actinomyces viscosus Biofilm. Front Bioeng Biotechnol. 2022 Mar 3;10:864012.
[7] Kim DR, Martin S, Desai K. The effects of a comparatively higher dose of 1000 mg/kg/d of oral L- or D-arginine on the L-arginine metabolic pathways in male Sprague-Dawley rats. PLoS One. 2023 Aug 1;18(8):e0289476.
[8] Aso K, Nishigawa T, Nagamachi S, et al. Orally administrated D-arginine exhibits higher enrichment in the brain and milk than L-arginine in ICR mice. J Vet Med Sci. 2020 Mar 5;82(3):307-313.
H-D-Arg-OH是一种D-构型的非天然氨基酸,在药物开发和蛋白质工程中具有重要应用[1-2]。H-D-Arg-OH常被用于L-精氨酸/一氧化氮通路的相关研究,并显示出抑制某些癌细胞增殖的潜力[3-4]。
在体外,H-D-Arg-OH(10mM)预处理垂体GH3细胞15–240分钟,随后在正常Krebs溶液中孵育,显著增加细胞内D-精氨酸的浓度和一氧化氮(NO)的生成,同时提升细胞外亚硝酸盐水平[5]。8mM H-D-Arg-OH与0.01% α-淀粉酶(Amy)联合预处理粘性Actinomyces viscosus生物膜30分钟,显著增强α-淀粉酶对生物膜的解离作用,并彻底水解胞外多糖,同时保持对MC3T3-E1前成骨细胞的安全性[6]。
在体内,1000mg/kg/d H-D-Arg-OH通过饮水口服处理9周龄雄性Sprague-Dawley大鼠16周,显著增加肾脏和主动脉的内皮型一氧化氮合酶(eNOS)蛋白表达,同时提高骨骼肌中尿素水平[7]。H-D-Arg-OH(6mmol/10mL DW/kg)口服给药ICR小30分钟、60分钟和90分后观察到,口服H-D-Arg-OH显著增加H-D-Arg-OH在血浆和大脑中的水平[8]。
| Cell experiment [1]: | |
Cell lines | Pituitary GH3 cells (rat pituitary tumor cell line) and Bovine Aortic Endothelial Cells (BAEC) |
Preparation Method | GH3 cells were maintained in F10 medium supplemented with 10% FBS and 15% horse serum. BAEC were maintained in DMEM supplemented with 10% FBS. Cells were treated with H-D-Arg-OH or H-D-Arg-OH galactosyl derivative (D-ArgGal) at concentrations of 3-30mM for 30 minutes to 4 hours in normal Krebs solution at 37°C, 5% CO₂. |
Reaction Conditions | 3-30mM; 30min-4h |
Applications | H-D-Arg-OH significantly increased intracellular DAF-2 monitored NO and nitrite levels in a dose-dependent manner in GH3 cells. |
| Animal experiment [2]: | |
Animal models | Male Sprague-Dawley rats (9 weeks old) |
Preparation Method | Rats were orally administered L-arginine (L-Arg) or H-D-Arg-OH at a dose of 1000mg/kg/day in drinking water for 16 weeks. The control group received plain drinking water. Animals were sacrificed after the treatment period for analysis of plasma, organs, and tissues. |
Dosage form | 1000mg/kg/day; Oral (in drinking water); 16 weeks. |
Applications | Oral H-D-Arg-OH significantly increased endothelial nitric oxide synthase (eNOS) protein expression in the aorta and kidney compared to the control group. Oral H-D-Arg-OH significantly increased arginase I protein expression in the liver. H-D-Arg-OH significantly increased urea levels in the skeletal muscle and hydroxyproline levels in the kidney and brain. |
References: | |
| Cas No. | 157-06-2 | SDF | |
| 别名 | D-精氨酸,H-D-Arg-OH | ||
| 化学名 | (2R)-2-amino-5-(diaminomethylideneamino)pentanoic acid | ||
| Canonical SMILES | C(CC(C(=O)O)N)CN=C(N)N | ||
| 分子式 | C6H14N4O2 | 分子量 | 174.2 |
| 溶解度 | H2O : 25 mg/mL (143.51 mM; Need ultrasonic) | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.7405 mL | 28.7026 mL | 57.4053 mL |
| 5 mM | 1.1481 mL | 5.7405 mL | 11.4811 mL |
| 10 mM | 574.1 μL | 2.8703 mL | 5.7405 mL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















